2Sheikh MS,Huang Y. Death receptors as targets of cancer therapeutics.Curr Cancer Drug Targets.2004,4(1):97-104.
3Kischkel FC,Lawrence DA,Chuntharapai A,et al.Apo2L/TRAIL-dependent recruitment of endogenous FADD And Casper-8 to death receptors 4 and 5. Immunity,2000,12(6):611-620.
4Shivapurkar N, Toyooka S,Toyooka KO, et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer, 2004, 109(5):786-792.
5Miyashita T, Kawakami A, Nakashima T, et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblastlike synovial cells. Clin Exp ImmunoL 2004. 137(2):430-436.
6Almasan A,Ashkenazi A. Apo2L/TRAIL:Apoptosis signaling, biology,and potential for cancer therapy. Cytokine Growth Factor Rev,2003,14(3-4):337-348.
7Kim S,Choi K,Kwon D,et al.Ubiquitin-proteasome pathway as a primary defender against TRAIL-mediated cll death.Cell Mol Life Sci,2004,61(9):1075-1081.
8Wajant H.TRAIL and NFkappaB signaling-a complex relationship.Vitam Horm, 2004,67:101-132.
9Nakshatri H,Rice SE,Bhat-Nakshatri P.Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing hgand through sustained activation of c-Jun N-terminal kinase.Oncogene,2004,23(44):7330-7344.
10Valente P,Arzani D,Cesario A,et al.TNF increases camptothecin-induced apoptosis by inhibition of NF-kappaB.Eur J Cancer,2003,39 (10):1468-1477.
